Biosimilar Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Type (Adalimumab, Bevacizumab, Infliximab, Rituximab, Trastuzumab, Others), By Indication (Oncology, Autoimmune diseases, Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Biosimilar Monoclonal Antibodies Market Size

The global biosimilar monoclonal antibodies market size was valued at USD 17.35 billion in 2025 and is projected to grow from USD 20.18 billion in 2026 to USD 67.53 billion by 2034, registering a CAGR of 16.3% during the forecast period from 2026 to 2034. North America dominated the biosimilar monoclonal antibodies market with a market share of 38.2% in 2025.

Biosimilar monoclonal antibodies (mAbs) are biologic drugs designed to be highly similar to already approved reference monoclonal antibodies, with no clinically meaningful differences in safety, purity, or effectiveness. Produced using living cells, these antibodies are crucial in treating conditions such as cancer, autoimmune diseases, and inflammatory disorders. Rigorous testing ensures biosimilars match the efficacy of original biologics, offering a cost-effective alternative that enhances patient access to essential treatments.

The global market is experiencing rapid growth, driven by the rising demand for affordable biologic therapies, the increasing prevalence of chronic diseases, and expanding regulatory approvals. As healthcare systems worldwide seek to reduce the financial burden of high-cost biologics, biosimilars provide a viable solution, improving treatment accessibility in key therapeutic areas such as oncology, immunology, and ophthalmology.

Greater acceptance among physicians and patients supported by real-world evidence and robust post-marketing surveillance is further accelerating adoption. Moreover, advancements in bioprocessing techniques and analytical methods are further propelling market growth, enhancing the efficiency and scalability of biosimilar production. Meanwhile, government initiatives promoting biosimilar adoption and the ongoing expiration of patents for reference biologics are unlocking new opportunities.

Type Insights

The Adalimumab segment holds the largest share, driven by its widespread use in treating autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease. The loss of patent exclusivity for Humira has enabled multiple biosimilar entries, increasing competition and lowering treatment costs. Moreover, regulatory support, interchangeability designations, and favorable reimbursement policies have accelerated adoption across major healthcare markets, ensuring broader patient access and fueling market growth.

Request Customizationto receive a tailored report.

Indication Insights

The oncology segment leads the global market due to the high global cancer burden and rising demand for cost-effective treatments. Biosimilars of bevacizumab, trastuzumab, and rituximab play a crucial role in therapies for breast cancer, lymphoma, and colorectal cancer. Moreover, increasing regulatory approvals by the FDA, EMA, and PMDA have enhanced biosimilar penetration, significantly reducing treatment costs while maintaining efficacy. As healthcare systems push for affordable cancer care, the adoption of oncology biosimilars continues to rise.

Distribution Channel Insights

Hospital pharmacies dominate the market, serving as primary distribution centers for oncology and autoimmune disease treatments. These pharmacies ensure controlled access, physician supervision, and insurance coverage, facilitating safe and efficient patient care. Moreover, government and insurer-driven reimbursement initiatives encourage hospitals to prioritize biosimilars, driving wider adoption. With growing hospital reliance on biosimilars for cost-effective biologic treatments, hospital pharmacies continue to play a pivotal role in expanding market access and affordability.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America leads the global biosimilar monoclonal antibodies market, supported by a favorable regulatory environment, substantial healthcare expenditure, and rapid adoption of biosimilars. The FDA’s Biologics Price Competition and Innovation Act (BPCIA) has simplified the approval process, facilitating quicker market entry. Robust reimbursement policies, government incentives, and insurer backing have further encouraged healthcare providers to adopt biosimilars more widely.

Moreover, the presence of major industry players like Amgen Inc., Pfizer Inc., and Mylan N.V. bolsters market growth. The increasing demand for affordable biologics, combined with growing acceptance among healthcare providers, continues to drive biosimilar uptake in oncology, immunology, and inflammatory diseases throughout the region.

U.s. Biosimilar Monoclonal Antibodies Market Trends

The U.S. dominates the market, driven by high R&D investments, strong regulatory support, and the launch of innovative biosimilars. The FDA’s streamlined approval pathways facilitate rapid market entry. In May 2024, Biocon Biologics received FDA approval for its biosimilar Aflibercept (Yesafili), marking its expansion into the U.S. ophthalmology market. This milestone strengthens Biocon’s portfolio, enhances affordability, and improves patient access.

Asia-Pacific is poised for the fastest CAGR growth, driven by expanding biosimilar manufacturing capabilities, increasing regulatory approvals, and rising healthcare investments. Countries such as China, India, Japan, and South Korea are leading biosimilar production, supported by government initiatives, local biopharmaceutical innovations, and cost-driven healthcare reforms. Moreover, strategic collaborations between global and regional biopharma companies are enhancing biosimilar accessibility, making the region a major hub for biosimilar development and commercialization.

Singapore’s biosimilar market is rapidly expanding, driven by value-based healthcare policies and government initiatives. For instance, in September 2024, Singapore’s Agency for Care Effectiveness (ACE) implemented value-driven strategies, increasing biosimilar adoption to 95% within a year for infliximab, adalimumab, trastuzumab, rituximab, and bevacizumab. This initiative resulted in over 80% price reductions and projected $136 million in savings over five years, enhancing access to affordable biologics.

India’s biosimilar monoclonal antibodies industry is witnessing rapid growth, driven by high disease burden and increasing biosimilar approvals. In May 2023, Alkem Oncology launched Cetuxa, a biosimilar of Cetuximab, for head and neck cancer. Approved by the Drugs Controller General of India (DCGI), this biosimilar was developed by Enzene Biosciences Limited. The launch reinforces India’s focus on affordability, accessibility, and local manufacturing, making biosimilars more accessible to critically ill patients.

Japan’s market for biosimilar monoclonal antibodies is growing due to favorable regulatory policies and increasing commercialization efforts. In January 2025, Biocon Biologics Ltd (BBL) announced that Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved Ustekinumab BS subcutaneous injection [YD], a biosimilar to Stelara (Ustekinumab). This biosimilar, developed by Biocon and commercialized by Yoshindo Inc., expands affordable immunology treatment options, reinforcing Japan’s commitment to cost-effective biologic therapies.

Unlock Regional Insightsto access country-level data, & regional trends.

List of Key and Emerging Players in Biosimilar Monoclonal Antibodies Market